CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.